Monitor for interim safety and efficacy signals from the Phase 1b trial in 2027; upcoming mid-2026 update on future combination plans may provide additional catalysts. No immediate revenue potential, but successful data could enhance partnership or licensing prospects.
Price Chart
Executive Summary
C4 Therapeutics has dosed the first patient in a Phase 1b trial combining its investigational drug cemsidomide with Pfizer's FDA-approved elranatamab for relapsed/refractory multiple myeloma. The trial aims to evaluate safety and preliminary efficacy, with data expected in mid-2027, representing a strategic step in advancing cemsidomide across multiple treatment lines.
Key Facts
- First patient dosed in a Phase 1b trial combining cemsidomide with elranatamab (ELREXFIO®) for relapsed/refractory multiple myeloma (RRMM).
- Trial will evaluate cemsidomide at 50 µg, 75 µg, and 100 µg doses in combination with elranatamab; up to 54 patients to be enrolled.
- Primary endpoint is safety and tolerability; secondary endpoints include overall response rate, MRD-negative complete response, and duration of response.
- Pfizer is providing elranatamab at no cost under a clinical trial collaboration agreement; C4T is sponsoring and conducting the trial.
- Phase 1b data anticipated in mid-2027; part of a broader strategy that includes the ongoing Phase 2 MOMENTUM trial.
Financial Impact
No direct financial impact disclosed; trial costs expected to be partially offset by Pfizer's drug supply.
Risk Factors
- Clinical development risk: Combination therapy may show unacceptable toxicity or lack of efficacy.
- Dilution risk: C4T may need to raise capital to fund ongoing trials, potentially diluting shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262063 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $3.03 (−29.07%) |
Aug 14, 2026 6w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $3.03 (−29.07%) |
Aug 11, 2026 7w ago | 8-K | $3.62 $4.18 | ▲ +15.47% | ▲ +15.87% | $3.03 (−16.44%) |
Jun 11, 2026 16w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | $3.03 (−21.83%) |
May 15, 2026 19w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | $3.03 (−6.06%) |
May 12, 2026 20w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $3.03 (−4.57%) |
May 12, 2026 20w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $3.03 (−4.57%) |
Apr 9, 2026 25w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $3.03 (+6.89%) |
Apr 9, 2026 25w ago | Press Release | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $3.03 (+6.89%) |
Mar 25, 2026 27w ago | Press Release | $2.69 $2.70 | ▲ +0.37% | ▲ +0.62% | $3.03 (+12.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access